Why the study?
Does ISIS 304801 reduce triglyceride levels in patients with hypertriglyceridemia?
Does ISIS 304801 reduce triglyceride levels in patients with hypertriglyceridemia?
Antisense inhibition of APOC3 with ISIS 304801 significantly lowers triglyceride levels in patients with hypertriglyceridemia.
Supports triglyceride lowering via APOC3 inhibition in hypertriglyceridemia; confirms RCT efficacy of ISIS 304801.
We found that treatment with ISIS 304801 was associated with significant lowering of triglyceride levels, among patients with a broad range of baseline levels, through selective antisense inhibition of APOC3 synthesis. (Funded by Isis Pharmaceuticals; ClinicalTrials.gov number, NCT01529424.).
No takes yet. Share an insight, caveat, or question.
Gaudet et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: